The Alliance for Regenerative Medicine Announces 2016 Regen Med and Advanced Therapies State of the Industry Briefing

– January 6, 2016

WASHINGTON, D.C., January 6, 2016 – The Alliance for Regenerative Medicine (ARM), the international organization representing the gene therapy, cell therapy and tissue engineering sectors, announced its 2016 Regen Med & Advanced Therapies State of the Industry briefing will take place January 11, 2016 in San Francisco.

The briefing will provide a comprehensive industry update detailing key sector trends and metrics, anticipated clinical data events, recent advances and the outlook for the coming year.

The briefing will serve as a top-level gathering of more than 300 key stakeholders from the cell therapy, gene therapy and immuno-oncology fields, featuring sessions with industry experts, CEOs and senior executives from leading companies in the sector.

Program Agenda:

8:00 – 8:20am  
Introduction & Industry Update
Morrie Ruffin, Managing Director, Alliance for Regenerative Medicine
Edward Lanphier, Chairman, Alliance for Regenerative Medicine; President & CEO, Sangamo BioSciences

8:20 – 9:05am 
2016 Sector Forecast: Upcoming Clinical Data Events
Jason Kolbert, Head of Healthcare Research & Senior Managing Director, Maxim Group (moderator)
Eduardo Bravo, CEO, TiGenix
Silviu Itescu, Managing Director & CEO, Mesoblast
Sven Kili, VP & Head of Gene Therapy Development, GlaxoSmithKline
Jeffrey Walsh, COO, bluebird bio
Sue Washer, President & CEO, AGTC

9:05 – 9:50am
The Promise of Regenerative Medicine & Advanced Therapies in Oncology
Joshua Schimmer, Managing Director & Senior Research Analyst, Piper Jaffray (moderator)
Usman Azam, Global Head, Cell & Gene Therapies Unit, Novartis
André Choulika, Chairman & CEO, Cellectis

“The gene and cell therapy and broader regenerative medicine sectors continue to drive development of transformative therapies for a variety of unmet medical needs,” said Morrie Ruffin, managing director of ARM. “The past year saw significant gains in the clinic, sustained investor interest and a robust partnering environment. We look forward to addressing the new challenges and opportunities in the coming year.”

The briefing will take place at the Parc 55 Hotel in San Francisco from 8:00 a.m. to 9:50 a.m. The event is free and open to the public; however, registration is required. The complete agenda is available online

This briefing is held in conjunction with the Biotech Showcase™ 2016 investor conference, organized by EBD Group and Demy Colton. Attendance at this briefing is separate from registering to attend the Biotech Showcase™ 2016 conference, which requires paid registration. For full details on Biotech Showcase™ 2016, please visit the website:

About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 225 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit